Anrukinzumab
Anrukinzumab (IMA-638[1]) is a humanized monoclonal antibody designed for the treatment of asthma.[2]
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | IL13 |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| Chemical and physical data | |
| Formula | C6452H9954N1714O2024S46 |
| Molar mass | 145.4 kg/mol g·mol−1 |
  | |
Anrukinzumab was developed by Wyeth.
References
- "Wyeth.com | Complete Project Listing". Wyeth. 2008. Archived from the original on June 12, 2008. Retrieved November 19, 2008.
- Statement On A Nonproprietary Name Adopted By The USAN Council: Anrukinzumab, American Medical Association.
This article is issued from
Wikipedia.
The text is licensed under Creative
Commons - Attribution - Sharealike.
Additional terms may apply for the media files.